AG
MCRB icon

Algert Global’s Seres Therapeutics MCRB Stock Holding History

Algert Global’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,082
Closed -$139K – 1217
2022
Q3 		$139K Sell
1,082
-863
-44% -$88.4K 0.01% 1079
2022
Q2 		$133K Hold
1,945
– – 0.01% 1080
2022
Q1 		$277K Buy
1,945
+921
+90% +$142K 0.02% 967
2021
Q4 		$171K Buy
1,024
+131
+15% +$20.8K 0.02% 876
2021
Q3 		$124K Buy
+893
New +$175K 0.02% 956

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Algert Global's MCRB Position: Q4 2022 in Review

Algert Global sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 1,082 shares — an estimated $139K sold.

Algert Global first reported a position in MCRB in Q3 2021 and held it in 5 quarters. The position peaked at $277K in Q1 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

  • Algert Global reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Algert Global sold 1,082 Seres Therapeutics shares in Q4 2022, an estimated $139K.
  • Algert Global first reported a position in Seres Therapeutics in Q3 2021 and held it in 5 quarters.
  • Algert Global's Seres Therapeutics position peaked at $277K in Q1 2022.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Algert Global's 13F filing for Q4 2022, filed 14 Feb 2023.